The Lock and Key of Medicine: Monoclonal Antibodies and the Transformation of Healthcare
The untold story of monoclonal antibodies--the molecular heroes of biotechnology that revolutionized the diagnosis and treatment of more than fifty major diseases
This book is the first to tell the extraordinary yet unheralded history of monoclonal antibodies. Often referred to as Mabs, they are unfamiliar to most nonscientists, yet these microscopic protein molecules are everywhere, quietly shaping our lives and healthcare. Discovered in the mid-1970s in the laboratory where Watson and Crick had earlier unveiled the structure of DNA, Mabs have radically changed understandings of the pathways of disease. They have enabled faster, cheaper, and more accurate clinical diagnostic testing on a vast scale. And they have played a fundamental role in pharmaceutical innovation, leading to such developments as recombinant interferon and insulin, and personalized drug therapies such as Herceptin. Today Mabs constitute six of the world's top ten blockbuster drugs and make up a third of new introduced treatments.
Lara V. Marks recounts the risks and opposition that a daring handful of individuals faced while discovering and developing Mabs, and she addresses the related scientific, medical, technological, business, and social challenges that arose. She offers a saga of entrepreneurs whose persistence and creativity ultimately changed the healthcare landscape and brought untold relief to millions of patients. Even so, as Marks shows, controversies over Mabs remain, and she examines current debates over the costs and effectiveness of these innovative drugs.
What people are saying - Write a review
We haven't found any reviews in the usual places.
1 Hunting for the Elusive Magic Bullet
Patents Politics and Process
3 Breakthroughs at the Bench
4 The First Medical Applications
Early Clinical Tests
6 The Wild West of Antibody Commercialization
7 The Challenge of Monoclonal Antibody Drugs
A Renaissance for Mab Therapeutics
Other editions - View all
accessed achieved addition animals Annual Anti antigens application approval began Biology biotechnology blood body bone Cambridge Cambrosio cancer cause cell line Centocor clinical clonal selection colleagues cost created culture detect diagnostic disease drug early effective engineering established et al experience genes genetic given helped History human hybridoma immune immune system Immunology important improve industry infections initially Institute interferon Interview involved Journal July Keating known Koprowski laboratory later lymphocytes lymphoma Mab therapeutics Mabs major marrow Medical Medicine method mice million Milstein Monoclonal Antibodies mouse MSTN Murray myeloma Nature needed offered organ patients percent possible production proteins proved reagents received Report response Science scientists Sera-Lab serum soon specific success surface taken technique therapeutics therapy tion tissue treat treatment trials tumor typing United University Waldmann